- United States
- /
- Medical Equipment
- /
- NasdaqCM:NUWE
Is CHF Solutions, Inc. (NASDAQ:CHFS) Spending Too Much Money?
CHF Solutions, Inc. (NASDAQ:CHFS) shareholders, and potential investors, need to understand how much cash the business makes from its core operational activities, as well as how much is invested back into the business. After investment, what’s left over is what belongs to you, the investor. This also determines how much the stock is worth. Today we will examine CHF Solutions’s ability to generate cash flows, as well as the level of capital expenditure it is expected to incur over the next couple of years, which will result in how much money goes to you.
View our latest analysis for CHF Solutions
What is CHF Solutions's cash yield?
Free cash flow (FCF) is the amount of cash CHF Solutions has left after it pays off its expenses, including its net capital expenditures, which is what the company needs to spend each year to maintain or grow its business operations.
The two ways to assess whether CHF Solutions’s FCF is sufficient, is to compare the FCF yield to the market index yield, as well as determine whether the top-line operating cash flows will continue to grow.
Free Cash Flow = Operating Cash Flows – Net Capital Expenditure
Free Cash Flow Yield = Free Cash Flow / Enterprise Value
where Enterprise Value = Market Capitalisation + Net Debt
The business reinvests all its cash profits as well as borrows more money, to maintain and grow the company. This leads to a negative FCF, as well as negative FCF yield, in which case is not a very useful measure.
Does CHF Solutions have a favourable cash flow trend?
CHF Solutions’s FCF may be negative today, but is operating cash flows expected to improve in the future? Let’s examine the cash flow trend the company is anticipated to produce over time. In the next couple of years, CHF Solutions is expected to deliver a decline in operating cash flow compared to the most recent level, which is not an encouraging sign. Below is a table of CHF Solutions’s operating cash flow in the past year, as well as the anticipated level going forward.| Current | +1 year | +2 year | |
|---|---|---|---|
| Operating Cash Flow (OCF) | -US$14.6m | -US$14.8m | -US$8.2m |
| OCF Growth Year-On-Year | 1.9% | -45% | |
| OCF Growth From Current Year | -44% |
Next Steps:
Not only does CHF Solutions offer a yield above the market index, its operating cash flow growth in the short run further strengthens its case as a solid company to invest in going forward. Now you know to keep cash flows in mind, I suggest you continue to research CHF Solutions to get a better picture of the company by looking at:
- Historical Performance: What has CHFS's returns been like over the past? Go into more detail in the past track record analysis and take a look at the free visual representations of our analysis for more clarity.
- Management Team: An experienced management team on the helm increases our confidence in the business – take a look at who sits on CHF Solutions’s board and the CEO’s back ground.
- Other High-Performing Stocks: If you believe you should cushion your portfolio with something less risky, scroll through our free list of these great stocks here.
We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.
A landmark settlement is meant to punish Meta (META). If the 1998 tobacco deal is any guide, it might protect it.

Any moat with an opt-out clause for your competitors is just a fence around your own garden.
Worth looking at what previous legal action actually did to Meta rather than reaching for tobacco. The FTC's record five billion dollar privacy fine in 2019 was met with the stock rising, because it came in below fears and removed an open question. GDPR was designed to constrain large platforms and increased their share of the European ad market, because compliance cost fell hardest on small intermediaries. The FTC's antitrust case, the one that could genuinely have broken the company up, was decided in Meta's favour last November. The only thing that ever meaningfully hurt the business was Apple changing a tracking default, and Meta out-spent that too, while the ad-tech firms that could not afford to rebuild disappeared. The pattern is not that Meta survives regulation. It is that regulation keeps costing its smaller competitors more.
Andrew LeggetGreat earnings season, but are the earnings real?

About NasdaqCM:NUWE
Nuwellis
A medical device company, develops, manufactures, and commercializes medical devices used in ultrafiltration therapy.
Slight risk with mediocre balance sheet.